Dr. Xiayang Qiu, founder and CEO of Regor Therapeutics Group, is a visionary leader with proven track records in structural-based drug design across therapeutic areas and modalities. He established the Regor CARD (Computer Accelerate Rational Discovery) technology platform that delivered a dozen development candidates for major unmet needs, such as the leading oral small molecule GLP-1R full agonist RGT-075 for obesity and other metabolic diseases, and the unique CDK4+ inhibitor RGT-419B potentially as a next generation standard therapy for breast cancers.

Before founding Regor, he built and led industry-leading teams in broad disciplines of structural and molecular sciences and established the first high-resolution cryo-EM laboratory in industry. He is the inventor of the blockbuster RSV vaccine Abrysvo, the first-ever vaccine approved for maternity immunization to prevent infant infections.

Dr. Qiu graduated from Peking University and received his PhD from Michigan State. He was an NIH postdoctoral fellow at the University of Washington. He authored over 60 publications (8,000 citations) and a dozen patents. He has trained 15 postdocs and served on expert review panels for the National Institutes of Health.